Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 5/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27497725 | 0.81 | NOS2 (0.53) | SLC6A9NOS2MEN1KMT2AALDH1A1 | |
| SCHEMBL6504145 | 0.81 | NOS2 (0.69) | NOS2MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL6501942 | 0.80 | NOS2 (0.67) | NOS2MEN1KMT2ALMNA | |
| SCHEMBL6499310 | 0.79 | NOS2 (0.48) | SLC6A9NOS2MEN1KMT2AALDH1A1 | |
| SCHEMBL20917087 | 0.76 | FFAR1 (0.51) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL7429997 | 0.74 | CYP2D6 (0.57) | SLC6A9KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5280197 | 0.74 | CYP2D6 (0.57) | SLC6A9KMT2AALDH1A1LMNAMAPT | |
| Oxalic Acid SCHEMBL11350914 | 0.73 | SLC6A4 (0.57) | SLC6A9 | |
| SCHEMBL21051927 | 0.73 | SLC6A9 (0.51) | SLC6A9ALDH1A1MAPT | |
| SCHEMBL11357415 | 0.72 | CHRNB2 (0.57) | SLC6A9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1235870-C | Novel use of phenyl hetero alkylamine derivatives | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | CN | disclosed |
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1263711-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| CN-1411435-A | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | CN | disclosed |
| EP-1263711-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062704-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | SLC6A9 3751/4885NOS2 3/4885MEN1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.